סימזיה
neopharm ltd, israel - certolizumab pegol - תמיסה להזרקה - certolizumab pegol 200 mg/ml - certolizumab pegol
טייסברי
medison pharma ltd - natalizumab - תרכיז להכנת תמיסה לאינפוזיה - natalizumab 300 mg / 15 ml - natalizumab - natalizumab - tysabri is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis . to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations. the safety and efficacy of tysabri beyond two years are unknown. because tysabri increases the risk of progressive multifocal leukoencephalopathy (pml), an opportunistic viral infection of the brain that usually leads to death or severe disability. tysabri is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate multiple sclerosis therapies. safety and efficacy in patients with chronic progressive multiple sclerosis have not been studied.
נוקלה אבקה להכנת תמיסה להזרקה
glaxo smith kline (israel) ltd - mepolizumab - אבקה להכנת תמיסה לזריקה - mepolizumab 100 mg - mepolizumab
נוקלה תמיסה להזרקה
glaxo smith kline (israel) ltd - mepolizumab - תמיסה להזרקה - mepolizumab 100 mg / 1 ml - mepolizumab
אנטיביו תוך ורידי
takeda israel ltd - vedolizumab - אבקה להכנת תמיסה מרוכזת לעירוי - vedolizumab 300 mg/vial - vedolizumab
אנטיביו תת עורי
takeda israel ltd - vedolizumab - תמיסה להזרקה - vedolizumab 158.8 mg / 1 ml - vedolizumab
אוקרוואס
roche pharmaceuticals (israel) ltd - ocrelizumab - תרכיז להכנת תמיסה לאינפוזיה - ocrelizumab 30 mg/ml - ocrelizumab
טקפידרה 120 מג
medison pharma ltd - dimethyl fumarate - dimethyl fumarate 120 mg - dimetyl fumarate
טקפידרה 120 מג
medison pharma ltd - dimethyl fumarate - dimethyl fumarate 120 mg - dimetyl fumarate
טקפידרה 120 מג
medison pharma ltd - dimethyl fumarate - dimethyl fumarate 120 mg - dimetyl fumarate